Carcinoid syndrome | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Carcinoid syndrome is characterized by a number of symptoms, physical signs, and unusual test results. Carcinoid syndrome is a term used to describe people who have an underlying carcinoid tumor that has spread to their liver. According to estimates, there are 1.5 to 1.9 clinical carcinoid tumour cases for every 100,000 people; however, since many carcinoid tumours do not cause the associated illness, the true incidence is unquestionably higher. The growth of the carcinoid syndrome medication market over the course of the forecast period will be significantly fueled by the expansion of knowledge about available treatments and technological advancement.

Description

A number of symptoms, physical manifestations, and unusual test results are indicative of the illness known as carcinoid syndrome. Carcinoid syndrome is a term used to describe people who have an underlying carcinoid tumor that has spread to their liver. Carcinoid tumors, which are well-differentiated neuroendocrine tumors with secretory characteristics, release serotonin and other active peptides. Because these tumors can grow anywhere in the primitive gut, they are frequently observed in the bronchial tree (airways) and gastrointestinal system. The migration or metastasis of tumor cells may occur in the liver. The small intestine and appendix are where carcinoid tumours most frequently develop, despite the fact that 10% of them begin in the lung. Other organs affected include the kidney, prostate, breast, ovary, thymus, colon, pancreas, stomach, and others. These slow-growing cancers frequently spread to the lymph nodes and liver, despite the fact that they can metastasize to the lung, bone, brain, and skin.

Carcinoid syndrome (Epidemiology)

According to estimates, there are 1.5 to 1.9 cases of clinical carcinoid tumours for every 100,000 people; however, since many carcinoid tumours do not result in the associated illness, the true incidence is unquestionably higher. It is estimated that 8,000 new cases of carcinoid tumours linked to the GI system are diagnosed in the US every year. Carcinoid syndrome affects both sexes equally. The majority of cicinoids' victims are people between the ages of 50 and 70. The typical age at diagnosis is 10 to 93 years old (mean age is 55 years).

Carcinoid syndrome -Current Market Size & Forecast Trends

The market for carcinoid syndrome management was valued at approximately USD 1.77 billion in 2023 and is expected to grow to around USD 4.99 billion by 2033, reflecting a compound annual growth rate (CAGR) of 10.9% during this period. This growth is driven by the increasing prevalence of carcinoid tumors, advancements in diagnostic technologies, and the development of new treatment options, including somatostatin analogs and targeted therapies. Additionally, rising awareness among healthcare providers and patients about carcinoid syndrome is contributing to market expansion. The market is projected to continue its upward trend through 2035, supported by ongoing research and development efforts aimed at improving treatment efficacy and patient outcomes.

Throughout the forecast period, the growth of the carcinoid syndrome medication market will be largely driven by the expansion of knowledge about available treatments and technological development. The incidence of an unhealthy lifestyle, an unbalanced diet, and a lack of exercise is also contributing to the growth of the market for medications for carcinoid syndrome. On the other hand, during the forecast period, the rise in treatment and diagnostic costs will be a significant factor impeding the growth of the market for medications for carcinoid syndrome. In the coming years, there are also likely to be opportunities for the carcinoid syndrome medicine market to grow due to increased adoption of the most recent formulations and dosage forms. Octreotide (Chiasma), Paltusotine (Crinetics Pharmaceuticals), and other new medications have potential to drive market.

Report Highlights

Carcinoid syndrome - Current Market Trends

Carcinoid syndrome - Current & Forecasted Cases across the G8 Countries

Carcinoid syndrome - Market Opportunities and Sales Potential for Agents

Carcinoid syndrome - Patient-based Market Forecast to 2035

Carcinoid syndrome - Untapped Business Opportunities

Carcinoid syndrome - Product Positioning Vis-a-vis Competitors' Products

Carcinoid syndrome - KOLs Insight